Purpose Osseous metastases often undergo an osteoblastic healing response following chemotherapy. The purpose of our study was to demonstrate the quantitative CT changes in attenuation of osseous metastases before and after chemotherapy. Materials and methods Our study was IRB approved and HIPAA compliant. Our cohort consisted of 86 consecutive cancer patients with contrast-enhanced CTs before and 14 ± 2 (12-25) months after initiation of chemotherapy (60 ± 11 years, 36 males, 50 females). The average and maximum metastasis attenuations were measured in Hounsfield units (HU) by two readers. Treatment effects were assessed using paired t-tests and Fisher exact tests. Intraclass correlation coefficients (ICCs) were calculated. Patient records were reviewed to determine the patient's clinical status (worse, unchanged, or improved) at the time of follow-up CT. Results The distribution of lesion types was as follows: lytic (30/86, 35%), blastic (43/86, 50%), and mixed lytic-blastic (13/86, 15%). There was a significant increase in average and maximum CT attenuation of metastases following chemotherapy for all patients, which remained statistically significant when stratified by lesion type, clinical status (worsening or improving/stable), cancer type (breast, lung), and radiation therapy (P < 0.05). In a subgroup of patients whose osseous metastases decreased in average attenuation (14/86, 16%), more patients had a worse clinical status (11/14, 79%) (P = 0.02). ICC was almost perfect for average attenuation and substantial for maximum attenuation. Conclusion Quantitative assessment of osseous metastatic disease using CT attenuation measurements demonstrated a statistically significant increase in attenuation more than 12 months after initiation of chemotherapy.
Introduction
Osseous metastatic disease is common, affecting approximately 280,000 adults in the USA, with approximately 68% of cases occurring in patients with primary breast, prostate, or lung cancer. Accurate evaluation of the imaging findings of osseous metastatic disease is important for staging, treatment planning, and prognosis [1] [2] [3] [4] [5] .
Osseous metastases can undergo an osteoblastic response following chemotherapy. Initially observed in skeletal scintigraphy and described as a Bflare phenomenon,^apparent discordance between clinical improvement of the patient and worsening imaging findings has also been described for radiography, positron emission tomography (PET), and computed tomography (CT) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The description of the flare phenomenon on CT has been limited to case series [15] [16] [17] [18] , and no large quantitative study on the effect of chemotherapy on CT attenuation of osseous metastases has been performed. Furthermore, the numeric values associated with CT attenuation before and after chemotherapy and their temporal change are not known.
The purpose of our study was therefore to demonstrate the quantitative CT changes in attenuation of osseous metastases before and after chemotherapy.
Materials and methods

Patient cohort
Our study was IRB approved and HIPAA compliant.
Inclusion criteria were age ≥ 18 years, history of cancer, presence of osseous metastases, and contrast-enhanced CT of the chest, abdomen, and pelvis before any chemotherapy treatment as well as 12 or more months after the initiation of chemotherapy.
Our patient database was queried for all adult patients with abdominal/pelvic CTs from July to October 2014. There were a total of 9102 patients; 1726 had non-contrast CTs, and these patients were excluded. Of the remaining 7376 patients, 3576 patients' examinations were performed for malignancy. All 3490 patients without a CT at the presentation of osseous metastases who did not have a CT before or at least 12 months after the initiation of chemotherapy were excluded, leaving a cohort of 86 patients. A total of 172 pre-and post-treatment CT scans were evaluated.
CT technique
Lesions were evaluated using either a 16-or 64-slice CT (Siemens Biograph 16 or 64, Siemens, Erlangen, Germany or GE Healthcare discover, Milwaukee, WI, USA).
All metastatic lesions were identified and evaluated on either a CT of the chest or a CT of the abdomen and pelvis [slice thickness, 2.5 mm for chest and 5 mm for abdomen/pelvis; table feed, 15 mm/s; pitch 1.5; tube voltage, 80-140 kVP; tube current, variable (maximum 450) mAs; sagittal and coronal reconstruction thickness, 2 mm with 2 mm intervals] with IV and with or without oral contrast. For abdomen/pelvis CT studies, the portal venous phase was used. Only IV contrastenhanced studies were evaluated for both the baseline and follow-up scans to decrease variability.
Patient clinical status
The clinical status of the patient at the time of the postchemotherapy CT scan was determined by reviewing the medical record and other imaging studies performed within 1 month, including the CT scan, after chemotherapy. The patient was considered to have a worse clinical status if there was evidence of (1) local tumor enlargement or recurrence at the site of the primary tumor, (2) new or enlarging metastases, and (3) increase of serologic markers (e.g., PSA). The patient was considered to have a stable or improved clinical status if there was evidence of (1) local tumor at the primary site decreased or unchanged in size, (2) metastases decreased or unchanged in size, and (3) serologic markers (e.g., PSA) decreased or unchanged. These findings were confirmed with the oncologist's assessment through the oncology notes in the patient's medical record.
Attenuation measurements
All CT scans were evaluated on a Picture Archiving and Communication System (PACS) workstation (Agfa, Morstel, Belgium) by two musculoskeletal radiologists with 6 and 5 years of experience (CYC and FJS).
The CT of the chest or abdomen/pelvis was reviewed for each patient, and the largest osseous metastatic lesion on axial slices was selected by reader 1 and reader 2 in consensus. Each lesion was also qualitatively evaluated on the CT scan prior to chemotherapy as lytic, blastic, or mixed lytic-blastic by comparing the lesion to the adjacent, normal vertebral body by reader 1 and reader 2 in consensus.
Subsequently, attenuation measurements were independently performed by reader 1 and reader 2, with each reader blinded to the other readers' results. The rounded region of interest (ROI) tool was used to draw the largest possible ROI over the lesion on axial images, without extending beyond lesion margins or including an adjacent cortex, to measure the average attenuation in Hounsfield units (HU). The ROI could be adjusted from a perfect circle to be ellipsoid to maximize the area of the lesion that was sampled (Fig. 1A) . The same axial slice was used to measure the maximum attenuation using the square histogram tool. If necessary, multiple ROIs were sampled to determine the highest attenuation (Fig. 1B) . The square was permitted to extend beyond the margins of the lesion if the lesion was soft tissue, but the cortex was always excluded. The histogram tool provided the range of densities and the number of pixels for each attenuation value. The maximum attenuation in HU was recorded (Fig. 1C) .
The lesion was measured in the same location on the studies before and after chemotherapy. The type of lesion (lytic, blastic, mixed lytic-blastic) and the patient's overall disease status in terms of serum markers and imaging findings other than osseous metastases were recorded. If the evaluated metastasis was also included in the radiation field, this information was recorded. If the patient received radiation that did not include the evaluated metastasis (e.g., brain radiation, but a lumbar spine metastasis was evaluated), this patient was not considered to have received radiation therapy to the osseous metastasis.
Statistical analysis
The averages and standard deviations for each patient's largest lesion were calculated, and groups were compared using the paired t-test or Fisher exact test (JMP, version 12 Pro, SAS Institute, Cary, NC). P < 0.05 was considered statistically significant. Interreader reproducibility was assessed using the intraclass correlation coefficient (ICC) with a 95% confidence interval (CI) (MedCalc 
Results
Patient cohort
The patient cohort consisted of 86 patients, with 36/86 (42%) males and 50/86 (58%) females, ages 60 ± 11 (range 34-80) years. The distribution of primary tumors was as follows: breast (33/86, 38%), lung (20/86, 23%), prostate (9/86, 10%), pancreas (6/86, 7%), and other (liver, bladder, kidney, rectum, esophagus, thyroid, ovary, melanoma, malignant hemangiopericytoma, nasopharyngeal, leiomyosarcoma of unknown origin) (18/86, 21%). The average time between the two CT studies was 14 ± 2 months, with a range of 12 to 25 months.
The measured lesions were in the following locations: spine/sacrum (63/86, 73%), pelvis (20/86, 23%), and sternum (3/86, 3%). The distribution of lesion types was as follows: lytic (30/86, 35%), blastic (43/86, 50%), and mixed lyticblastic (13/86, 15%). CT image through T8 before chemotherapy demonstrates an osteoblastic metastasis along the anterior aspect of the vertebral body. A rounded ROI was drawn within the lesion. The shape can be adjusted from a perfect circle to ovoid, and can also be rotated, to maximize the ROI within the lesion. The average and maximum attenuations are 470 and 521 HU, respectively. (B) Axial contrast-enhanced CT image in the same patient through T8 12 months after the initiation of chemotherapy again demonstrates an osteoblastic metastasis, increased in attenuation and now with average and maximum attenuations measuring 638 and 843 HU, respectively. The square ROI tool is used to sample multiple regions within the lesion, taking care not to traverse the cortex. (C) Histogram from maximum density measurement from image B shows a distribution of HU values. The maximum value (oval) was recorded as the maximum attenuation. At the time of the post-chemotherapy CT, the patient had stable existing and no new disease on MRI of the brain and CT of the neck, chest, abdomen, and pelvis, consistent with overall stable clinical status All of the patients received chemotherapy between the two CT scans. Twenty-two (22/86, 26%) also received radiation therapy to the evaluated osseous metastasis.
CT attenuation of metastatic lesions
The average and maximum CT attenuation and the quantitative CT changes in attunation of contrast-enhanced osseous metastases before and after chemotherapy are detailed in Tables 1 and 2 . There was a significant increase in average and maximum CT attenuation of osseous metastases following chemotherapy for lytic (Fig. 2), blastic (Fig. 3) , and mixed lytic-blastic (Fig. 4) lesions.
The difference remained statistically significant when stratified by the two most common cancer types in our cohort (breast and lung) for both the average and maximum CT attenuations and for both reader 1 and reader 2 ( Tables 1 and 2 ).
The patients who received radiation and chemotherapy were compared with the patients who received only chemotherapy. There was no significant difference of lesion CT average and maximum attenuation before and after chemotherapy for reader 1 and reader 2 (P > 0.05). The average and maximum CT attenuations for patients with chemotherapy and radiation to the evaluated metastases are detailed in Tables 1 and 2 .
Patients with radiation and chemotherapy to the evaluated osseous metastasis also showed a statistically significant increase in average and maximum attenuation (Tables 1 and 2 ). There was no statistically significant difference between the CT attenuation of the osseous metastases before (average attenuation, reader 1: P = 0.6; reader 2: P = 0.6) (maximum attenuation, reader 1: P = 0.1; reader 2: P = 0.6) and after (average attenuation, reader 1: P = 0.8; reader 2: P = 0.8) (maximum attenuation, reader 1: P = 0.5; reader 2: P = 0.7) chemotherapy when comparing patients with and without radiation therapy.
There was a subgroup of 14/86 (16%) patients whose osseous metastases decreased in average attenuation (same for both reader 1 and reader 2). The average attenuation decreased 103 ± 96 (14-294) HU for reader 1 and 122 ± 102 (10-321) for reader 2. The distribution of lesion types among the patients with a decreased average attenuation were as follows: lytic (4/14, 29%), blastic (6/14, 43%) (Fig. 5) , and mixed lytic-blastic (3/14, 21%). There was no significant difference in the distribution of lesion type (lytic, blastic, mixed) between patients whose metastases increased or decreased in attenuation (P = 0.5). The clinical status of patients who had a decrease in their CT attenuation was more often worse (11/ 14, 79%) than unchanged (3/14, 21%). No patients' clinical status was improved. For the patients where the CT attenuation of the osseous metastasis was increased, the clinical status was more often unchanged or improved Table 1 Average attenuations before and after chemotherapy for both readers (46/86, 53%) than worse (40/86, 47%). A higher proportion of the patients with decreased CT attenuation of the osseous metastasis had a worse clinical status compared to patients with increased CT attenuation of the osseous metastasis (P = 0.02). The ICC for reader 1 and reader 2's average attenuation measurements was 0.96 (95% CI, 0.94-0.97, almost perfect agreement) before chemotherapy and 0.97 (95% CI, 0.96-0.98, almost perfect agreement) after chemotherapy. The ICC for reader 1 and reader 2's maximum attenuation measurements was 0.79 (95% CI, 0.67-0.86, substantial agreement) before chemotherapy and 0.77 (95% CI, 0.79-0.91, substantial agreement) after chemotherapy.
Discussion
Our quantitative assessment of osseous metastases using CT attenuation measurements confirms a statistically significant increase in average and maximum contrastenhanced CT attenuation 12 months or more after initiation of chemotherapy.
The osteoblastic healing response by imaging has been of great interest to oncologists because of the potential implications for patient care. In these situations, the patient's tumor markers, such as prostate-specific antigen (PSA), are decreasing, and other metastases may be decreasing in size. However, the osseous lesions appear progressed by imaging, as manifested by an increase in the number and attenuation of lesions. Pollen et al. initially described an osteoblastic response after chemotherapy by radiography. They observed an increase in the number and attenuation of metastases in patients with prostate cancer on radiography with concurrent improvement on technetium-99m-methylene diphosphonate skeletal scintigraphy (bone scan) and a decreasing PSA and suggested that the osteoblastic response may represent response to therapy rather than worsening disease. This article cautioned against interpreting the imaging findings in isolation, i.e., without the clinical context. If the patient is erroneously thought to have worsening osseous metastases, they may go on to have more aggressive treatment. Alternatively, they may be considered as a nonresponder to their current therapy or may fail to qualify for other types of therapy if they are thought to have progressive disease on treatment. The management and prognosis could differ drastically [12] .
We found a statistically significant increase in CT attenuation of osseous metastases following chemotherapy. The osteoblastic healing response has been qualitatively demonstrated in prior studies. Stattaus et al. described an osteoblastic healing response with an average increase in CT attenuation of 153 HU in a series of 15 patients with Table 2 Maximum attenuations before and after chemotherapy for both readers small cell lung cancer after treatment with chemotherapy [16] . Messiou et al. reported three patients with prostate cancer who showed an increase in the number, size, and attenuation of sclerotic lesions on CT but a falling PSA after treatment with chemotherapy. These patients remained stable at follow-up, consistent with an osteoblastic healing response [17] . Quattrocchi et al. demonstrated a quantitative increase of CT attenuation in lytic Fig. 2 A 50-year-old female with lung cancer. (A) Axial contrastenhanced CT at initial cancer diagnosis demonstrates a lytic osseous metastasis in the right sacrum (*). The average attenuation is 87 HU, and the maximum attenuation is 304 HU. (B) Axial contrast-enhanced CT 13 months after initiation of chemotherapy demonstrates increased attenuation of lytic osseous metastasis in the sacrum (*). The average attenuation is 184 HU, and the maximum attenuation is 975 HU. At the time of the post-chemotherapy CT, the patient had developed new brain metastases, and her lung metastases were enlarging, consistent with overall worsening of clinical status Fig. 3 A 72-year-old male with prostate cancer. (A) Axial contrastenhanced CT at initial cancer diagnosis demonstrates a blastic osseous metastasis in the right half of the L5 vertebral body (solid arrow). The average attenuation is 228 HU, and the maximum attenuation is 459 HU. There is a second lesion in the left anterior aspect of the vertebral body (dashed arrow). (B) Anterior and (C) posterior projection of the pelvis from technetium-99m-methylene diphosphonate skeletal scintigraphy from the same day as the CT demonstrates uptake in the L5 vertebral body (ovals) corresponding to the lesions seen on CT (arrows). (D) Axial contrast-enhanced CT 14 months after initiation of chemotherapy demonstrates increased attenuation of the blastic osseous metastasis in the L5 vertebral body (solid arrow). The second lesion in the left anterior aspect of the vertebral body has also increased in attenuation (dashed arrows). The average attenuation is 473 HU, and the maximum attenuation is 670 HU. At the time of the post-chemotherapy CT, the patient's PSA had increased from 0.4 to 7, consistent with overall worsening of clinical status and sclerotic metastases after 3 months of bisphosphonate (zoledronic acid) administration but did not study chemotherapeutic agents [18] . A similar Bflare^phenomenon has been described for bone scan [7, 8] and for PET [13] [14] [15] , as manifested by increased radiotracer activity. Prior studies have suggested that tumor cells can incite osteoblastic activity and that chemotherapy can lead to an osteoblastic healing response [12, [16] [17] [18] [19] [20] [21] [22] [23] .
Patients whose clinical status was worsening as well as patients whose clinical status was improving or remained unchanged had a statistically significant increase in the attenuation of their metastases. Therefore, the overall attenuation of the lesion cannot be interpreted in isolation to determine the clinical status of the patient. Other imaging findings and serologic markers should be used in the interpretation of the change in lesion attenuation. A statistically higher proportion (79% versus 47%) of the patients with a decrease in the CT attenuation of the osseous metastasis had a worse clinical status, suggesting that an overall decrease in the attenuation of osseous metastases may reflect a worsening of the patient's overall clinical status. Again, this finding should not be interpreted in isolation but in the context of the patient's other clinical and imaging findings. Also, mixed responses to treatment can occur where one organ system responds and another does not. Future prospective studies would help to clarify the role of CT attenuation changes of contrast-enhanced osseous metastases before and after chemotherapy in the evaluation of overall response to treatment.
Many questions remain, such as the temporal relationship of CT attenuation changes following therapy. We selected 1 year as the minimum duration of follow-up to capture changes in CT attenuation. The change in attenuation likely occurs much earlier. In the study by Quattrocchi et al., an increase in CT attenuation was detected after 3 months of therapy [18] . Because our study was retrospective, we did not have followup studies at fixed time points. Prospective studies with evaluation at fixed intervals (e.g., 3, 6, 9, and 12 months) are necessary to assess temporal changes in attenuation.
Our observed decrease in CT attenuation of some lesions also poses interesting questions, especially in the light of the manuscript by Yamashita et al., which suggested that the osteoblastic response may reflect response to therapy [24] . Although we did not see a statistically significant difference between the lesion types (lytic, blastic, mixed lytic-blastic) within the subgroup where the CT attenuation decreased, the number of lesions that decreased in attenuation was small (N = 14). We did observe a greater proportion of the patients with lesions with decreased attenuation who had a worse clinical status compared with patients who had lesions that increased in attenuation. This difference was statistically significant. However, the cohort with decreased lesion attenuation was small (N = 14), and further studies are needed to elucidate the association of osseous metastasis attenuation and overall clinical status. Contrast enhancement affects the CT attenuation of vertebral bodies [25] . To minimize the confounding effects of contrast enhancement, and because most CT scans performed for malignancy staging and follow-up are contrast enhanced, we only included patients who had undergone contrast-enhanced CTs using identical protocols. However, the use of contrastenhanced studies raises the question of the contribution of tumor vascularity changes to the change in attenuation [26, 27] . Overall, the osteoblastic response should be much more likely to cause an increase in attenuation as opposed to the increased vascularity because the increased attenuation from the contrast will reach a lower maximum attenuation as compared to sclerotic bone. Also, when reviewing the studies, none of the lytic lesions appeared to be enhancing. As discussed by O'Sullivan et al. [26] , lytic lesions are more aggressive compared to sclerotic lesions, so by inference it is unlikely that the >150 HU increase in density was solely related to contrast enhancement. For our study, we only measured the attenuation of the largest lesion in each patient, but in a previous study done by the authors, we found that there was no significant variation in osseous metastasis attenuation within the same patient [28] .
Limitations of our study include the retrospective study design, which precludes standardization of the chemotherapy regimen and the interval of the follow-up studies. A lower agreement between the readers in the measurement of the maximum attenuation was observed, which may be related to the heterogeneity of treated lesions. We found that the results remained statistically significant when we stratified by the two most common cancers, but because of the retrospective design of the study, we could not control for the type and duration of the chemotherapy. Future prospective studies should involve cohorts focused on specific types of cancer.
In conclusion, osseous metastatic disease typically increases in attenuation after chemotherapy. Knowledge of this phenomenon is important in the evaluation of osseous metastases, and an increase in attenuation should not be considered Fig. 4 A 59-year-old female with breast cancer. (A) Axial contrastenhanced CT at initial cancer diagnosis demonstrates a mixed lytic/ blastic osseous metastasis in the T7 vertebral body (arrow). The average attenuation is 330 HU, and the maximum attenuation is 716 HU. (B) Axial contrast-enhanced CT 13 months after initiation of chemotherapy demonstrates increased attenuation of mixed lytic/blastic osseous metastasis in T7 (arrow). The average attenuation is 859 HU, and the maximum attenuation is 1107 HU. At the time of the post-chemotherapy CT, the patient had stable existing and no new disease on MRI of the cervical and thoracic spine and CT of the neck, chest, abdomen, and pelvis. In addition, her CEA and CA 15-3 tumor markers were within normal limits, consistent with no change of clinical status overall synonymous with Bworsening of disease.^Changes in CT attenuation of the osseous metastases should always be interpreted in the context of the patient's clinical and other imaging findings.
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